A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations.
Public ClinicalTrials.gov record NCT05355701. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A PHASE 1, OPEN-LABEL, DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND ANTI TUMOR ACTIVITY OF PF-07799933 (ARRY-440) AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS 16 YEARS AND OLDER WITH ADVANCED SOLID TUMORS WITH BRAF ALTERATIONS
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this clinical trial is to learn about the safety and effects of the study medicine (called PF-07799933) administered as a single agent and in combination with other study medicines in people with solid tumors. This study is seeking participants who have an advanced solid tumor with a certain type of abnormal gene called "BRAF" and available treatments are no longer effective in controlling their cancer. All participants in this study will receive PF-07799933. PF-07799933 comes as a tablet to take by mouth, 2 times a day. Depending on the part of the study, participants may also receive another study medicine: * People with melanoma or other solid tumors may also receive binimetinib. Binimetinib comes as a tablet to take by mouth, 2 times a day. * People with colorectal cancer may also receive cetuximab or cetuximab and mFOLFOX6 (Chemotherapy regimen). Cetuximab will be given weekly (or every two weeks) in the clinic as a shot given in the vein or port (intravenous, IV). Participants may receive the study medicines for about 2 years. The study team will monitor how each participant is doing with the study treatment during regular visits at the study clinic.
Study identification
- NCT ID
- NCT05355701
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 103 participants
Conditions and interventions
Conditions
Interventions
- PF-07799933 Drug
- binimetinib Drug
- cetuximab Biological
- midazolam Drug
- fluorouracil Drug
- leucovorin Drug
- oxaliplatin Drug
Drug · Biological
Eligibility (public fields only)
- Age range
- 16 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 4, 2022
- Primary completion
- Aug 30, 2027
- Completion
- Aug 30, 2027
- Last update posted
- Aug 31, 2026
2022 – 2027
United States locations
- U.S. sites
- 31
- U.S. states
- 11
- U.S. cities
- 16
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Highlands Oncology Group, PA | Fayetteville | Arkansas | 72703 | — |
| Highlands Oncology Group, PA | Rogers | Arkansas | 72758 | — |
| Highlands Oncology Group, PA | Springdale | Arkansas | 72762 | — |
| Clinical and Translational Research Center (CTRC) | Aurora | Colorado | 80045 | — |
| UCHealth Sue Anschutz-Rodgers Eye Center | Aurora | Colorado | 80045 | — |
| University of Colorado Hospital - Anschutz Cancer Pavilion (ACP) | Aurora | Colorado | 80045 | — |
| University of Colorado Hospital - Anschutz Inpatient Pavilion (AIP) | Aurora | Colorado | 80045 | — |
| University of Colorado Hospital - Anschutz Outpatient Pavilion (AOP) | Aurora | Colorado | 80045 | — |
| Sylvester Comprehensive Cancer Center | Miami | Florida | 33136 | — |
| University of Miami Hospital and Clinics | Miami | Florida | 33136 | — |
| Brigham and Women's Hospital | Boston | Massachusetts | 02115 | — |
| Dana-Farber Cancer Institute | Boston | Massachusetts | 02215 | — |
| Dana-Farber Cancer Institute - Chestnut Hill | Newton | Massachusetts | 02467 | — |
| Brigitte Harris Cancer Pavilion | Detroit | Michigan | 48202 | — |
| Henry Ford Cancer - Detroit (Brigitte Harris Cancer Pavilion) | Detroit | Michigan | 48202 | — |
| Henry Ford Medical Center - Columbus | Novi | Michigan | 48377 | — |
| CT Scan and Echo Only: Henry Ford Medical Center-Plymouth | Plymouth | Michigan | 48170 | — |
| MSK Monmouth | Middletown | New Jersey | 07748 | — |
| MSK David H. Koch Center for Cancer Care | New York | New York | 10021 | — |
| Memorial Sloan Kettering Cancer Center 53rd street | New York | New York | 10022 | — |
| Memorial Sloan Kettering Cancer Center | New York | New York | 10065 | — |
| Cleveland Clinic Taussig Cancer Center Investigational Pharmacy | Cleveland | Ohio | 44106 | — |
| Cleveland Clinic | Cleveland | Ohio | 44195 | — |
| Providence Cancer Institute Franz Clinic | Portland | Oregon | 97213 | — |
| Providence Portland Medical Center | Portland | Oregon | 97213 | — |
| Sarah Cannon Research Institute - Pharmacy | Nashville | Tennessee | 37203 | — |
| SCRI Oncology Partners | Nashville | Tennessee | 37203 | — |
| TriStar Bone Marrow Transplant | Nashville | Tennessee | 37203 | — |
| TriStar Centennial Medical Center - Cell Processing Lab | Nashville | Tennessee | 37203 | — |
| TriStar Centennial Medical center | Nashville | Tennessee | 37203 | — |
| START San Antonio | San Antonio | Texas | 78229 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 9 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05355701, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 31, 2026 · Synced Sep 2, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05355701 live on ClinicalTrials.gov.